Vaccine makers, and biopharmaceutical industry more generally, are encouraged to see the broad international support the COVAX Facility has received today. The 156 economies committed to participate in the Facility, including 64 higher income economies, represent the best chance the world has to ensure that by 2021, 64% of the global population has access to...
Read moreThomas Cueni, IFPMA Director General, spoke to BBC World Service Marketplace Morning Report about the efforts and challenges to produce and deliver a vaccine for COVID-19 Victoria Craig One of the keys to getting economies back to some form of normalcy is a vaccine. The US said that it could begin delivering one within 24...
Read moreInterview – Asahi TV Japan – Solidarity at the core of COVAX Facility Thomas Cueni, IFPMA Director General, spoke to Asahi TV in Japan on 18 September 2020 about COVAX and the importance of working together in order to guarantee a safe and effective vaccine in both richer and poorer countries. Here are top 5...
Read moreThe biopharmaceutical industry has made addressing the pandemic its top priority, devoting its resources, expertise, know-how, and intellectual assets to developing potential treatments and vaccines at record speed, while committing to and engaging in unprecedented levels of international collaboration and coordination through initiatives such as ACT-A, ACTIV and CEPI to ensure equitable access to products being developed. Thomas Cueni, Director General of...
Read moreThe latest G-Finder report “Landscape of Emerging Infectious Disease R&D: Preventing the next pandemic” shows that to be better prepared in the future, the R&D funding needs to be more diversified and supported by a wider range of funders. It also highlights the central role that product development partnerships (PDPs) and initiatives such as the...
Read moreToday I had the pleasure to participate in The New World Model, an online event on the future of industry, organised by the World Free Zones Organization. The event seeks to explore the different angles of the new industry business models likely to emerge in a post-pandemic landscape. I was joined by executives from large...
Read moreThis article first appeared in the Global Cause on the Infectious Diseases campaign. A printed publication was enclosed within every copy of New Scientist magazine and the content is available online on the Global Cause website. The campaign featured exclusive content from key thought leaders and industry voices about pharmaceutical industry collaboration in developing COVID-19...
Read moreWatch IFPMA Director-General Thomas Cueni, speak on the impact of the COVID-19 pandemic on the healthcare industry at The New World Model- The Future of Industry, organised by the World Free Zones Organization.
Read moreGeneva, 17 September 2020: Now more than ever, the adage “Health is Wealth” has heightened significance, with the COVID-19 pandemic highlighting the delicate and essential interdependence between public health and economic prosperity. The biopharmaceutical industry is working alongside governments worldwide to combat the burden of this unprecedented crisis, recognizing that unparalleled collaboration among all sectors...
Read moreIFPMA is strongly committed to rigorous regulatory standards for approval of COVID-19 treatments and vaccines. No matter how urgently action is needed against the coronavirus public health emergency, it is imperative that the highest standards of quality, safety and efficacy are upheld everywhere. IFPMA member companies are fully committed to transparency in reporting clinical trial...
Read moreOn 3rd September, CEOs from five companies – Pfizer, Roche, MSD, Gilead, and Lilly took part in the latest IFPMA COVID-19 virtual media briefing dedicated to the on-going efforts to find a treatment for COVID-19. During the course of the pandemic, we have witnessed a remarkable show of solidarity, partnership, and collaboration within the industry...
Read more